Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C. - Seite 3

Building on a legacy of commitment

While always dedicated to the production of plasma medicines, the Clayton site has operated under multiple names throughout its 50-year history, first beginning operations as Cutter Laboratories in 1974 before coming under the Miles Laboratories umbrella in 1983. In 1995, the site began to operate under the name of its parent company, Bayer, maintaining this brand for a decade until Talecris Biotherapeutics purchased it in 2005. Grifols acquired the Clayton site in 2011 and, with a mission to improve the health and well-being of people around the world, carried forward the site’s legacy of producing quality products to benefit patients. Today, Grifols employs more than 1,600 people onsite, with another 400 in nearby Research Triangle Park, the largest research park in the U.S.

MEDIA CONTACTS:

Grifols Press Office

[e-mail]
Tel. [phone]

Spain
Duomo Comunicación
Tel.: [phone]
Raquel Lumbreras (Tel. [phone])
[e-mail]

Borja Gómez (Tel. + 34 659 572 185)
[e-mail]

Investors
Investors Relations & Sustainability
[e-mail] - [e-mail]
Tel. [phone] 

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces, and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and Grifols’ ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company’s innovation in both plasma and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology, and infectious diseases.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world’s largest with over 390 across North America, Europe, Africa and the Middle East, and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.